Meriofert Set (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Both hormones bind to specific receptors on ovarian cells. Follicle‑stimulating hormone promotes growth and maturation of ovarian follicles, while luteinising hormone triggers the final maturation and release of the oocyte. Together they enhance estrogen production and coordinate the ovulatory process.

The dose of Meriofert Set is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian response, treatment protocol, and clinical goals. No standard regimen is provided in public information.

Meriofert Set is intended for use before conception to facilitate ovulation. Its safety during pregnancy has not been established, and it is not recommended for use while pregnant. Limited data are available for breastfeeding, so the product should be avoided unless the prescriber decides the benefit outweighs potential risk.

To place an order, submit an enquiry on the Meriofert Set product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Meriofert Set combines both LH and FSH in a single injectable formulation, whereas some alternatives provide only FSH or separate LH preparations. This combined approach can simplify dosing schedules and may better mimic natural ovarian physiology, but the choice depends on individual patient characteristics and the treating physician’s protocol.

Meriofert Set must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic technique when preparing the injection.

The product is supplied as an injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique. The injection site and volume are selected according to the prescribed dose and the patient’s treatment plan.

Serious risks include severe ovarian hyperstimulation syndrome, which can cause fluid accumulation, electrolyte imbalance, and thromboembolic events, as well as multiple pregnancy and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for abdominal pain, rapid weight gain, shortness of breath, or signs of allergic response.

Meriofert Set is contraindicated in individuals with known hypersensitivity to the product or any of its excipients, in women with active ovarian cysts that could be aggravated, and in patients with uncontrolled thyroid disease or severe cardiovascular conditions where hormonal stimulation poses additional risk.